Evidence map›Paper›PMID 42268209›Full record

Observational studyAntimicrobial agents and chemotherapy2026

A French national observatory of people with HIV initiating lenacapavir-based treatment after regulatory approval.

Charlotte Charpentier, Thomas Montrouge, Marc Wirden, Véronique Avettand-Fenoel, Camille Tumiotto, Pantxika Bellecave, Audrey Rodallec, Elisabeth Garnier, Djeneba Fofana, Sidonie Lambert-Niclot and 19 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Charlotte CharpentierService de Virologie, AP-HP, Hôpital Bichat-Claude Bernard, Université Paris Cité, INSERM, IAME, Paris, France.ORCID 0000-0002-6441-7054
Thomas MontrougeService de Virologie, Sorbonne Université, INSERM, UMR-S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, Paris, France.ORCID 0009-0004-5262-4533
Marc WirdenService de Virologie, Sorbonne Université, INSERM, UMR-S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, Paris, France.
Véronique Avettand-FenoelLI2RSO, CHU d'Orléans, Service de Virologie, Université d'Orléans, Orléans, France.
Camille TumiottoService de Virologie, CHU de Bordeaux, CNRS-UMR 5234 Microbiologie Fondamentale et Pathogénicité, Université de Bordeaux, Bordeaux, France.
Pantxika BellecaveService de Virologie, CHU de Bordeaux, CNRS-UMR 5234 Microbiologie Fondamentale et Pathogénicité, Université de Bordeaux, Bordeaux, France.
Audrey RodallecCHU Nantes, Service de Virologie, Nantes, France.
Elisabeth GarnierCHU Nantes, Service de Virologie, Nantes, France.
Djeneba FofanaDépartement de Virologie, Santé Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique APHP, Hôpital Saint-Antoine, Paris, France.
Sidonie Lambert-NiclotDépartement de Virologie, Santé Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique APHP, Hôpital Saint-Antoine, Paris, France.
Brigitte MontèsService de Virologie, CHU de Montpellier, Montpellier, France.
Marie-Laure ChaixService de Virologie, INSERM UMR 1342, AP-HP, Hôpital Saint-Louis, Université Paris Cité, Paris, France.
Caroline CharreService de Virologie, INSERM UMR 1342, AP-HP, Hôpital Saint-Louis, Université Paris Cité, Paris, France.
Pierre GantnerService de Virologie, CHU de Strasbourg, Strasbourg, France.
Magali Bouvier-AliasService de Virologie, AP-HP, Hôpital Henri Mondor, Créteil, France.
Enagnon Kazali AlidjinouLaboratoire de Virologie ULR3610, Univ Lille, CHU de Lille, Lille, France.
Pauline CoulonLaboratoire de Virologie ULR3610, Univ Lille, CHU de Lille, Lille, France.
Gilbert MchantafLI2RSO, CHU d'Orléans, Service de Virologie, Université d'Orléans, Orléans, France.
Agnès Beby-DefauxService de Virologie, CHU de Poitiers, Poitiers, France.
Elodie Alessandri-GradtDepartment of Virology, National Reference Center of HIV, Univ Rouen Normandie, Université de Caen Normandie, INSERM, Normandie Univ, DYNAMICURE UMR 1311, CHU Rouen, Rouen, France.ORCID 0000-0002-8906-3416
Alice MoisanDepartment of Virology, National Reference Center of HIV, Univ Rouen Normandie, Université de Caen Normandie, INSERM, Normandie Univ, DYNAMICURE UMR 1311, CHU Rouen, Rouen, France.
Quentin Le HingratService de Virologie, AP-HP, Hôpital Bichat-Claude Bernard, Université Paris Cité, INSERM, IAME, Paris, France.ORCID 0000-0001-9017-4941
Minh LêService de Pharmacologie, AP-HP, Hôpital Bichat-Claude Bernard, INSERM, IAME, Paris, France.
Constance DelaugerreService de Virologie, INSERM UMR 1342, AP-HP, Hôpital Saint-Louis, Université Paris Cité, Paris, France.
Anne-Geneviève MarcelinService de Virologie, Sorbonne Université, INSERM, UMR-S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, Paris, France.
Gilles PeytavinService de Pharmacologie, AP-HP, Hôpital Bichat-Claude Bernard, INSERM, IAME, Paris, France.
Vincent CalvezService de Virologie, Sorbonne Université, INSERM, UMR-S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, Paris, France.
Diane DescampsService de Virologie, AP-HP, Hôpital Bichat-Claude Bernard, Université Paris Cité, INSERM, IAME, Paris, France.
Lenacapavir Observatory Study Group

Funding

Agence Nationale de Recherches sur le Sida et les Hépatites ViralesGilead Sciences
6 · The paper itself

Abstract

There is limited data on lenacapavir (LEN) use, the newest capsid inhibitor, in observational settings. We describe population characteristics and pharmaco-virological outcomes of people with HIV-1 (PWH) who initiated LEN-based treatment. We conducted a national retrospective observational study of PWH initiating LEN-based treatment in France after its approval (December 2022). Virological failure (VF) was defined as two consecutive viral loads (VLs) ≥50 c/mL, and a non-virological response as a VL decrease of <1 log

Indexed as

Anti-HIV AgentsHIV-1HIV InfectionsAcetamidesAdultDrug Resistance, ViralFemaleFranceHumansIndazolesMaleRetrospective StudiesViral LoadAcetamidesAnti-HIV AgentsIndazoleslenacapavircabotegravirdrug resistanceHIVlenacapavir

Identifiers

PMID42268209
PMCPMC13321793

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.